keyword
MENU ▼
Read by QxMD icon Read
search

Xelox

keyword
https://www.readbyqxmd.com/read/27760964/-a-case-of-early-anal-canal-cancer-with-pagetoid-spread-with-different-antitumor-effects-of-chemotherapy-on-different-metastatic-sites
#1
Kazuhiko Yoshimatsu, Gakuji Osawa, Hajime Yokomizo, Yuki Yano, Sachiyo Okayama, Akiko Sakuma, Masaya Satake, Yasufumi Yamada, Shinichi Asaka, Takebumi Usui, Kentaro Yamaguchi, Shunichi Shiozawa, Takeshi Shimakawa, Takao Katsube, Yoshihiko Naritaka
A 78-year-old man visited our hospital with a prolapsed hemorrhoid. He was referred to the dermatology unit due to the thickness and redness of the perianal skin. He was diagnosed as having extra mammary Paget's disease by skin biopsy. After a biopsy of the anal polyp was performed to investigate the primary site, he was diagnosed with early anal canal cancer with Pagetoid spread and underwent a radical operation. Abdominoperineal resection with skin(D2 prx D3 lymphadenectomy) was performed with perineal reconstruction using a gracilis muscle graft...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27760939/-remarkable-response-to-trastuzumab-observed-in-a-case-of-gastric-cancer-with-her2-negative-conversion
#2
Nobutoshi Horii, Daisuke Morioka, Kazuya Yamaguchi, Yoshiki Sato
A 64-year-old woman was diagnosed with advanced gastric cancer with solitary liver metastasis. Although the HER2 status of the tumor was IHC2+, no further examination for HER2 status using FISH was performed. Four courses of S-1 and cisplatin chemotherapy were administered. The primary lesion and metastatic lesion were confirmed to have partially regressed. After 4 courses of chemotherapy, an open total gastrectomy, D2 dissection, pancreatosplenectomy, and posterior segmental hepatectomy were performed. Her postoperative course was uneventful...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27680076/-application-study-on-regional-infusion-chemotherapy-by-celiac-trunk-during-operation-in-advanced-gastric-cancer-patients
#3
Xiaolan You, Haixin Qian, Lei Qin, Yuanjie Wang, Wenqi Li, Yanjun Lian, Xiaojun Zhao, Ning Xu, Chuanjiang Huang, Zhiyi Chen, Guiyuan Liu
OBJECTIVE: To explore the feasibility, safety and efficacy of intraoperative regional infusion chemotherapy by celiac trunk in advanced gastric cancer patients. METHODS: One hundred and twenty-six patients with advanced gastric cancer(stageII(-III() were screened from database of Gastrointestinal Surgery Department of Taizhou People's Hospital between January 2008 and December 2010 who underwent R0 resection and D2 lymphadenectomy, received postoperative chemotherapy(XELOX or FOLFOX), and had complete follow-up data...
September 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27664112/plasma-levels-of-trastuzumab-in-gastric-cancer-case-report
#4
González G Jonathan, Alonso Á Beatriz, Gloria Julia Nazco C, Batista L Norberto, Gutiérrez N Fernando
INTRODUCTION: The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. CASE REPORT: We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5...
September 23, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27646021/erratum-to-the-comet-open-label-phase-ii-study-of-neoadjuvant-folfox-or-xelox-treatment-combined-with-molecular-targeting-monoclonal-antibodies-in-patients-with-resectable-liver-metastasis-of-colorectal-cancer
#5
Masato Kataoka, Mitsuro Kanda, Kiyoshi Ishigure, Hiroshi Matsuoka, Yusuke Sato, Takao Takahashi, Chihiro Tanaka, Tomohiro Deguchi, Yoshihisa Shibata, Mikinori Sato, Hitoshi Inagaki, Takanori Matsui, Akinobu Kondo, Nao Takano, Haruyoshi Tanaka, Junichi Sakamoto, Koji Oba, Ken Kondo
No abstract text is available yet for this article.
September 19, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27638675/the-comet-open-label-phase-ii-study-of-neoadjuvant-folfox-or-xelox-treatment-combined-with-molecular-targeting-monoclonal-antibodies-in-patients-with-resectable-liver-metastasis-of-colorectal-cancer
#6
Masato Kataoka, Mitsuro Kanda, Kiyoshi Ishigure, Hiroshi Matsuoka, Yusuke Sato, Takao Takahashi, Chihiro Tanaka, Tomohiro Deguchi, Yoshihisa Shibata, Mikinori Sato, Hitoshi Inagaki, Takanori Matsui, Akinori Kondo, Nao Takano, Haruyoshi Tanaka, Junichi Sakamoto, Koji Oba, Ken Kondo
BACKGROUND: Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established. The purpose of this study was to evaluate the efficacy and safety of oxaliplatin-based regimen (FOLFOX or XELOX) plus monoclonal antibodies (cetuximab or bevacizumab) treatment in patients with resectable CLM. METHODS: A single-arm, open-label, multicenter, phase II trial was conducted for patients aged ≥ 20 years with resectable and untreated CLM...
September 8, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27602586/efficacy-of-preoperative-chemotherapy-regimens-in-patients-with-initially-unresectable-locally-advanced-gastric-adenocarcinoma-capecitabine-and-oxaliplatin-xelox-or-with-epirubicin-eox
#7
Yan Wang, Rong-Yuan Zhuang, Yi-Yi Yu, Shan Yu, Jun Hou, Yuan Ji, Yi-Hong Sun, Kun-Tang Shen, Zhen-Bin Shen, Feng-Lin Liu, Nai-Qing Zhao, Tian-Shu Liu
Purpose We assessed the effectiveness of EOX (capecitabine, oxaliplatin and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as preoperative chemotherapy for initially unresectable locally advanced gastric cancer.Methods This is a prospective observational study. Patients with unresectable locally advanced gastric cancer were performed EOX regimen or XELOX regimen at the discretion of the investigators. They were assessed for response every 2 cycles by CT (computed tomography) scan. A multidisciplinary team reassessed resectability after 4 cycles...
September 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27595400/primary-tumour-resection-could-improve-the-survival-of-unresectable-metastatic-colorectal-cancer-patients-receiving-bevacizumab-containing-chemotherapy
#8
Zhiming Wang, Li Liang, Yiyi Yu, Yan Wang, Rongyuan Zhuang, Yong Chen, Yuehong Cui, Yuhong Zhou, Tianshu Liu
BACKGROUND: The effect of primary tumour resection (PTR) among metastatic colorectal cancer (mCRC) patients remains controversial. Combination chemotherapy with bevacizumab could improve the clinical outcomes of these patients, which might change the importance of PTR in the multi-disciplinary treatment pattern. METHODS: We performed a non-randomized prospective controlled study of mCRC pts whose performance status (PS) scored ≤2 and who received bevacizumab combination chemotherapy (FOLFOX/XELOX/FOLFIRI) as a first-line therapy...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27574566/-magic-of-our-gastric-cancer-results-on-perioperative-chemotherapy
#9
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano
AIM: To determine reproducibility of perioperative chemotherapy for gastric cancer (GC) on our settings by identifying patient's overall survival and comparing them to larger studies. METHODS: Retrospective analysis of our series, where we present our eleven-year's experience on GC managed according to perioperative approach of three preoperative chemotherapy cycles followed by surgery and finally three postoperative chemotherapy cycles. Chemotherapic scheme used was Xelox (Oxaliplatin and Capecitabine)...
August 15, 2016: World Journal of Gastrointestinal Pathophysiology
https://www.readbyqxmd.com/read/27573560/phase-iii-trial-comparing-3-6-months-of-adjuvant-folfox4-xelox-in-stage-ii-iii-colon-cancer-safety-and-compliance-in-the-tosca-trial
#10
S Lonardi, A Sobrero, G Rosati, M Di Bartolomeo, M Ronzoni, G Aprile, M Scartozzi, M Banzi, M G Zampino, F Pasini, P Marchetti, M Cantore, A Zaniboni, L Rimassa, L Ciuffreda, D Ferrari, S Barni, V Zagonel, E Maiello, E Rulli, R Labianca
BACKGROUND: Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. A shorter duration of therapy, if equally efficacious, would be advantageous for patients and Health-Care Systems. PATIENTS AND METHODS: TOSCA ['Randomized trial investigating the role of FOLFOX-4 or XELOX (3 versus 6 months) regimen duration and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer] is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III radically resected colon cancer to receive 3 months (arm 3 m) versus 6 months (arm 6 m) of FOLFOX4/XELOX...
August 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27547057/tumor-markers-used-in-monitoring-the-tumor-recurrence-in-patients-with-colorectal-cancer
#11
Claudia Burz, Ben Youssef Mohamed Aziz, Loredana Bălăcescu, Luminiţa Leluţiu, Rareş Buiga, Gabriel Samasca, Alexandru Irimie, Cosmin Lisencu
BACKGROUND AND AIMS: The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer. METHODS: A total of 30 patients diagnosed with colon cancer stage II or III who underwent optimal surgery were enrolled in study. Tumor markers CEA and CA 19-9 were determined before surgery. Tumor samples were prepared using tissue microarray kit (TMA) then stained for different cellular markers (Ki 67, HER2, BCL2, CD56, CD4, CD8) and analyzed using Inforatio programme for quantitative determination...
2016: Clujul Medical (1957)
https://www.readbyqxmd.com/read/27507128/a-phase-ii-study-of-xelox-and-cetuximab-as-first-line-therapy-in-patients-with-kras-wild-type-metastatic-colorectal-cancer-fleet2-study
#12
Shoichi Hazama, Hiromichi Maeda, Shigeyoshi Iwamoto, Ho Min Kim, Hiroyoshi Takemoto, Kenji Kobayashi, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima
BACKGROUND: Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. PATIENTS AND METHODS: In this clinical trial we evaluated the efficacy and safety of weekly/biweekly cetuximab administration combined with biweekly XELOX in patients with previously untreated v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type mCRC...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27503580/cxcr4-polymorphism-predicts-progression-free-survival-in-metastatic-colorectal-cancer-patients-treated-with-first-line-bevacizumab-based-chemotherapy
#13
S Matsusaka, S Cao, D L Hanna, Y Sunakawa, M Ueno, N Mizunuma, W Zhang, D Yang, Y Ning, S Stintzing, A Sebio, S Stremitzer, S Yamauchi, A Parekh, S Okazaki, M D Berger, R El-Khoueiry, A Mendez, W Ichikawa, F Loupakis, H-J Lenz
We analyzed associations between CXCR4/CXCL12 single-nucleotide polymorphisms and outcomes in metastatic colorectal cancer (mCRC) patients who underwent first-line bevacizumab-based chemotherapy. A total of 874 patients were included in this study: 144 treated with bevacizumab and FOLFOX or XELOX (training cohort), 653 treated with bevacizumab and FOLFIRI or FOLFOXIRI (validation cohort A or B) and 77 treated with cetuximab- and oxaliplatin-based regimens (control cohort). One CXCR4 polymorphism (rs2228014) and two CXCL12 polymorphisms (rs1801157 and rs3740085) were analyzed by PCR-based direct sequencing...
August 9, 2016: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/27468238/observational-cohort-study-focused-on-treatment-continuity-of-patients-administered-xelox-plus-bevacizumab-for-previously-untreated-metastatic-colorectal-cancer
#14
Masahito Kotaka, Fusao Ikeda, Masaki Tsujie, Shinichi Yoshioka, Yoshihiko Nakamoto, Takaaki Ishii, Takahisa Kyogoku, Takeshi Kato, Akihito Tsuji, Michiya Kobayashi
BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27452754/-short-term-efficacy-comparison-between-preoperative-three-dimensional-conformal-radiotherapy-and-volumetric-modulated-arc-therapy-concurrently-combined-with-chemotherapy-in-the-treatment-of-locally-advanced-rectal-carcinoma
#15
Lin Xiao, Xin Yu, Yujia Zhu, Weiwei Xiao, Zhifan Zeng, Mengzhong Liu, Rong Zhang, Yuanhong Gao
OBJECTIVE: To compare the short-term efficacy and treatment-related adverse reaction between preoperative three dimensional conformal radiotherapy (3D-CRT) and volumetric modulated arc therapy (VMAT) concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma (LARC). METHODS: Clinical data of 334 patients with LARC undergoing preoperative 3D-CRT(172 cases) or VMAT(162 cases) with concurrent Xelox chemotherapy (main protocol: capecitabine plus oxaliplatin) and surgery in Sun Yat-sen University Cancer Center from May 2007 to April 2013 were retrospectively analyzed...
July 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27354648/adoptive-chemoimmunotherapy-using-activated-%C3%AE-%C3%AE-t-cells-for-stage-iv-colorectal-cancer
#16
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Kojima Daibo, Toshiyuki Mera, Toshihiro Tanaka, Keiko Naito, Kosei Yasumoto, Takashi Kamigaki, Shigenori Goto, Yuichi Yamashita, Suguru Hasegawa
BACKGROUND/AIM: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC). PATIENTS AND METHODS: Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy...
July 2016: Anticancer Research
https://www.readbyqxmd.com/read/27354605/bi-weekly-capecitabine-oxaliplatin-xelox-plus-bevacizumab-as-first-line-treatment-of-metastatic-colorectal-cancer-the-phoenix-trial
#17
Takanori Matsui, Naoki Nagata, Keiji Hirata, Satoshi Okazaki, Sumito Sato, Masato Nakamura, Homin Kim, Koji Oba, Junichi Sakamoto, Hideyuki Mishima
AIM: This phase II study assessed the efficacy and toxicity of an intermittent weekly capecitabine regimen in combination with oxaliplatin (XELOX) plus bevacizumab as a first-line treatment of metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with measurable mCRC who were to receive first-line chemotherapy were enrolled onto this disease-oriented multicenter phase II trial. Patients with mCRC were required to have Eastern Cooperative Oncology Group performance status of 0 to 1, to be aged >20 years, and to have adequate organ function...
July 2016: Anticancer Research
https://www.readbyqxmd.com/read/27353106/-expression-of-cd133-in-rectal-cancer-tissues-and-its-relationship-with-neoadjuvant-chemoradiotherapy
#18
Dongmei Li, Huanwen Wu, Ruie Feng, Dingrong Zhong, Yufeng Luo, Yi Xiao
OBJECTIVE: To investigate the association of CD133 expression in rectal cancer tissues with neoadjuvant chemoradiotherapy (nCRT) and tumor regression grading (TRG) after nCRT. METHODS: Radical resected rectal cancer specimens and clinicopathological data of 105 patients, including 60 men and 45 women with median age of 59 years, diagnosed as locally advanced rectal cancer in Peking Union Medical College Hospital from January 2008 to December 2014 were collected retrospectively...
June 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27353101/-clinical-study-on-locally-advanced-rectal-cancer-patients-with-pathological-complete-response-after-neoadjuvant-chemoradiotherapy
#19
Gong Chen, Rongxin Zhang, Xiaojun Wu, Zhenhai Lu, Peirong Ding, Zhizhong Pan, Desen Wan
OBJECTIVE: To explore the efficacy prediction of the locally advanced rectal cancer patients, especially those with pathological complete response(pCR), receiving neoadjuvant chemoradiotherapy in order to execute precise preoperative neoadjuvant chemoradiotherapy. METHODS: From January 2000 to January 2011, 125 patients diagnosed as locally advanced rectal cancer receiving preoperative neoadjuvant chemoradiotherapy in our department with complete data were enrolled in this study, including 85 males and 40 females with mean age of 54(15 to 77) years old...
June 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27270460/chronomodulated-oxaliplatin-plus-capecitabine-xelox-as-a-first-line-chemotherapy-in-metastatic-colorectal-cancer-a-phase-ii-brunch-regimen-study
#20
Kezban Nur Pilancı, Sezer Saglam, Alper Okyar, Serap Yucel, Zeliha Pala-Kara, Cetin Ordu, Esat Namal, Rumeysa Ciftci, Ulkuhan Iner-Koksal, Esra Kaytan-Saglam
PURPOSE: The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS: A total of 30 treatment-naïve colorectal cancer patients with metastatic disease were included. Oxaliplatin 130 mg/m(2) on day 1 plus chronomodulated oral capecitabine 2000 mg/m(2) per day were administered (50 % dose at 8:00 a...
July 2016: Cancer Chemotherapy and Pharmacology
keyword
keyword
2278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"